Progressive cardiac involvement in a compound heterozygote Fabry patient: a case report

Eliza Jeanette McConnell1*, James Every2, Michel Tchan3, and Rebecca Kozor1

1Cardiology Department, Royal North Shore Hospital, Sydney, Australia; 2Sydney Medical School, University of Sydney, Sydney, Australia; and 3Genetic Medicine, Westmead Hospital, Sydney, Australia

Received 5 October 2018; accepted 27 November 2018; online publish-ahead-of-print 7 December 2018

Background
Fabry disease is an X-linked lysosomal storage disorder due to mutations in the gene encoding for alpha-galactosidase A, with subsequent accumulation of complex sphingolipids in multiple organs, including the heart. Female heterozygotes can develop cardiac involvement although this is usually milder and slower to progress compared with male hemizygotes.

Case summary
A 71-year-old woman with two separate pathological Fabry mutations (N215S, C202R; compound heterozygote) presented with progressive cardiac involvement despite enzyme replacement therapy (ERT) with Replagal, as demonstrated by troponin elevation and cardiovascular magnetic resonance (CMR) findings: moderate segmental left ventricular dysfunction with wall thinning, low myocardial native T1, and extensive late gadolinium enhancement with co-located increased T2.

Discussion
We report for the first time, a detailed cardiac phenotype using CMR in a compound heterozygote Fabry patient with progressive cardiac involvement despite ERT.

Keywords
Case report • Fabry • Cardiovascular magnetic resonance • T1 mapping

Introduction
Fabry disease is a rare X-linked lysosomal storage disorder due to mutations in the gene encoding for alpha-galactosidase A, with subsequent accumulation of complex sphingolipids (e.g. globotriaosylceramide, Gb3) in multiple organs.1 Fabry disease can have a variety of phenotypes including neurological, cardiac, dermatological, and renal manifestations.

Despite being heterozygotes, women can be affected by the disease. However, generally women present later in life and progress slower than males (hemizygotes).2 Cardiovascular complications are the leading cause of premature death in Fabry disease, including in females.3,4

Learning points
• Women with Fabry disease may have cardiovascular involvement that tends to present later in life (in the sixth decade) and progress at a slower rate.
• The compound heterozygote genotype for Fabry disease is rare, but can present with a severe clinical phenotype.
• Cardiovascular magnetic resonance imaging is an important diagnostic modality for Fabry disease and can be used serially to demonstrate disease progression.

* Corresponding author. Email: eliza.mcconnell@hotmail.com
Handling Editor: Sabiha Gati
Peer-reviewers: Cemil Izgi, Sabiha Gati
Compliance Editor: Amir Aziz
Supplementary Material Editor: Peregrine Green
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Timeline

| Patient age | Patient events |
|-------------|----------------|
| 60 years    | Diagnosed with Fabry disease |
|             | • Enzyme replacement therapy (ERT) commenced for 3 weeks and then ceased due to non-compliance |
| 66 years    | Initial cardiac magnetic resonance (CMR) demonstrated: |
|             | • Moderate left ventricular hypertrophy |
|             | • Late gadolinium enhancement (LGE) |
|             | ERT is recommenced |
| 67–69 years | Recurrent paroxysmal atrial fibrillation necessitating pulmonary vein isolation on three occasions |
| 71 years    | Serial CMR demonstrated: |
|             | • New moderate segmental systolic dysfunction |
|             | • Progressive extensive transmural LGE |
|             | Raised troponin, brain natriuretic peptide, and mild decline in renal function noted on bloods at this time |

Case report

This is the case of a 71-year-old woman who was diagnosed with Fabry disease at age 60. She had normal renal function (eGFR 79 mL/min/1.73 m²), which deteriorated at a rate of -0.7 mL/min/1.73 m² per year during the subsequent 11 years. Genetic studies revealed the patient was a compound heterozygote with two separate mutations (N215S and C202R), one on each X chromosome. Her leucocyte a-gal activity was 0.111 nmol/min/mg protein (normal 0.7–3.3).

Diagnostic assessment

Initial cardiovascular magnetic resonance (CMR) at age 66, on a 3 T GE Healthcare MRI System, showed normal left ventricular (LV) cavity size (end diastolic volume 125 mL) and systolic function [LV ejection fraction (LVEF) 71%] with no regional wall motion abnormalities. It also showed moderate concentric LV hypertrophy [LVH; maximal wall thickness of 14 mm, LV mass (LVM) 203 g] and prominent papillary muscles. Dense mid-wall late gadolinium enhancement (LGE) was also evident in the classic basal inferolateral wall extending into the basal inferior wall, mid inferolateral wall, and apicolateral wall.

Interventions and outcomes

Enzyme replacement therapy (ERT) with Replagal (agalsidase alpha) was initially commenced, at age 60 but was discontinued after 3 weeks due to patient preference. Enzyme replacement therapy (Replagal) was recommenced at age 66 due to the CMR findings described above indicating cardiac involvement. Between the ages of 67 and 69 the patient had recurrent paroxysmal atrial fibrillation. Pulmonary vein isolation was performed on three occasions and was complicated on the last attempt by pericardial effusion requiring a pericardial window.

Serial CMR (1.5 T Siemens Aera) at age 71 demonstrated (Figure 1):

- a mildly dilated LV (LVEDV 160 mL) with moderate eccentric LVH—increased LVM (256 g) and maximal wall thickness of 17 mm in basal septum, but thinning of the basal-to-mid infarolateral and anterolateral walls (4 mm). New moderate segmental LV systolic dysfunction (LVEF 43%) with akinesis of the thinned segments. There was progressive extensive transmural LGE in the basal-to-mid inferolateral and anterolateral walls, extending into the apico-septal, and apicolateral walls, plus mid-wall LGE in the mid septum. T1 mapping revealed low myocardial native T1 (using MOdified Look-Locker Inversion recovery sequence) in the remote basal septum (889 ms; normal 1017 ± 37 ms). T2 mapping revealed increased T2 values in the LGE areas (59–63 ms; normal range 45 ± 6 ms) but normal T2 in the remote basal septum (48 ms).

Blood tests were significant for raised high sensitivity troponin I (126 ng/L; normal <14 ng/L), and elevated NT-pro BNP (193 pmol/L; normal <13 pmol/L), in the context of normal renal function (eGFR 72 mL/min/1.73 m²).

ECG showed sinus rhythm, LVH by Sokolov voltage criteria, incomplete left bundle branch block, and inferolateral T-wave inversion.

Discussion

This case reports for the first time, a detailed cardiac phenotype using CMR in a compound heterozygote Fabry patient with progressive cardiac involvement despite ERT.

Cardiovascular magnetic resonance was able to accurately detail the cardiac progression, namely—mild dilatation in LV cavity size (125–160 mL), increase in LVM (203–256 g), segmental thinning and akinesis of the LV with reduction in LV systolic function (LVEF 71–43%), and progression of LGE. The application of newer advanced tissue characterization techniques in the most recent scan showed—low T1 values in the septum representing sphingolipid storage, and high T2 values in the LGE areas coupled with elevated troponin levels suggesting myocardial inflammation.

Usually, hemizygote Fabry males demonstrate the classic disease features. However, it has been accepted for some time now that heterozygote females present with significant disease manifestations.

The mechanism behind the variation in the severity of organ involvement in female carriers is thought to be as a result of X-linked inactivation. There is, to the authors’ knowledge, only one case of a compound heterozygote and four cases of homozygotes (the same mutation on both X chromosomes) described in the literature regarding females with Fabry disease. Of these cases, two homozygotes presented without a clinical phenotype and the one female compound heterozygote had a mild non-cardiac variant.

Interestingly, the index patient was diagnosed as a compound heterozygote after her 48-year-old son with classical Fabry disease carried a separate mutation (C202R) to that of the index patient and her sister (N215S) (Figure 2). The son has ‘classic’ Fabry disease with renal involvement (including a history of renal transplantation) plus cardiac

![Figure 1](image1.png)

![Figure 2](image2.png)
involvement. His leucocyte a-gal activity was 0.100 nmol/min/mg protein. His CMR revealed: normal LV cavity size with moderate concentric LVH of 16 mm and hyperdynamic LV systolic function (LVEF 84%). Low native T1 in septum, and pseudonormal native T1 in the basal inferolateral wall suggestive of inflammation/fibrosis (note: no gadolinium was administered to assess for LGE). The older sister passed away from a stroke.

Fabry disease can be subdivided into classical and non-classical presentations, with classical patients defined in males by presentation with neuropathic pain, angiokeratoma and cornea verticillata, and long-term complications with renal, cardiac, and central nervous system disease. The ‘cardiac variant’ of Fabry disease represents a non-classical subgroup where disease manifestations are usually limited solely to the heart. N215S is an example of this with the predominant reported cardiovascular manifestation being LVH. The mutation C202R has not been previously described in the literature but is highly likely to be a classical mutation as the index patient’s son has classic disease, and two other mutations at this site (C202Y and C202W) are reported to cause classic Fabry disease.

In our patient, the presentation is most like older males who carry the N215S mutation. This is most likely consistent with her genotype, as the C202R allele contributes comparatively less to overall enzyme activity, leaving her with enzyme mostly generated from the N215S allele. However, X-chromosome inactivation is likely to have left a proportion of her cells expressing alpha galactosidase from the C202R allele only, thus potentially explaining her more severe cardiac phenotype when compared with those with the N215S mutation alone.

**Conclusion**

We report for the first time, a detailed cardiac phenotype using CMR in a compound heterozygote Fabry patient with progressive cardiac involvement despite ERT.
Supplementary material

Supplementary material is available at European Heart Journal - Case Reports online.

Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

Consent: The author/s confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient in line with COPE guidance.

Conflict of interest: R.K. has received honorary from Sanofi-Genzyme. M.T. reports being on disease specific advisory boards of Sanofi-Genzyme and Shire Pharmaceuticals, without personal financial remuneration.

References

1. Hoffmann B. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis 2009;4:21.
2. Kampmann C, Linhart A, Baehner F, Palecek T, Wiesthoff CM, Miebach E, Whybra C, Gal A, Bultas J, Beck M. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 2008;130:367–373.
3. Nordin S, Kozor R, Bulluck H, Castelletti S, Rosmini S, Abdel-Gadir A. Cardiac Fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy. J Am Coll Cardiol 2016;68:1705–1711.
4. Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006;43:347–352.
5. Oder D, Vergho D, Ertl G, Wanner C, Nordbeck P. Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation alleles. BMC Med Genet 2016;17:46.
6. Rodríguez-María A, Coll MJ, Chabás A. Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female. Hum Mutat 2003;22:258.
7. Ferreira S, Ortiz A, German DP, Vara-Baptista M, Caldeira-Gomes A, Camprecios M, Fenollar-Cortés M, Gallegos-Villalobos A, García D, García-Robles JA, Eigo J, Gutiérrez-Rivas E, Herrero JA, Mas S, Oancea R, Pérez P, Salazar-Martín LM, Solera-Garcia J, Alves H, Garman SC, Oliveira JP. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies. Mol Genet Metab 2015;114:248–258.
8. Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watson OT, Elliott PM, Linthorst GE, Wijburg FA, Biegstraaten M, Hollak CE. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol 2017;28:1631–1641.
9. Chimenti C, Pieroni M, Morgante E, Antuza D, Russo A, Russo MA, Maseri A, Frustaci A. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004;110:1047–1053.
10. Reuter C, Platt J. Clinical characteristics of the GLA N215S variant and implications for the diagnosis and management of nonclassic Fabry disease. Circ Cardiovasc Genet 2017;10:pii:e001918.
11. Germain DP, Brand E, Cecchi F, Kempf J, Laney DA, Linhart A, Marodi L, Nisholls K, Pieruzzi F, Shankar SP, Waldek S, Wanner C, Jovanovic A. The phenotypic characteristics of the p.N215S Fabry disease genotype in male and female patients: a multi-center Fabry Registry study. Mol Genet Metab 2017;120:551–552.
12. Saito S, Ohno K, Sakuraba H. Comparative study of structural changes caused by different substitutions at the same residue on α-galactosidase A. PLoS One 2013;8:e84267.
13. Ploos van Amstel JK, Jansen RP, de Jong JG, Hanel BC, Wevers RA. Six novel mutations in the alpha-galactosidase A gene in families with Fabry disease. Hum Mol Genet 1994;3:503–505.